Latest Administration News

Keybridge Capital Limited has appointed a voluntary administrator following a series of legal setbacks and an inability to raise crucial capital, leading to the suspension of its shares.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

Smartgroup has been appointed as the exclusive provider of salary packaging and novated leasing services for Monash Health’s 25,000 employees under a new multi-year contract starting April 2025.

Gladiator Resources Limited reported a $703,000 net cash outflow for the December 2024 quarter, driven by exploration and evaluation expenses, yet maintains sufficient capital to fund operations into 2025.

Black Dragon Gold has applied for its Salave Gold Project to be designated a Strategic Investment Project under new regional legislation in Asturias, aiming to fast-track development and boost local economic benefits.

Moho Resources has agreed to sell its Empress Springs Project in Western Queensland for $1.258 million, including deferred payments and a retained royalty, as it refocuses its portfolio.

CAR Group Limited has announced a semi-annual ordinary dividend of AUD 0.385 per share, partially franked at 50%, payable in April 2025. Shareholders can opt into a Dividend Reinvestment Plan with no discount, reflecting steady shareholder returns.

Ansell Limited has announced a USD 0.222 per share dividend for the six months ending December 2024, payable in March 2025 with a full dividend reinvestment plan available.

Ansell Limited delivered a robust FY25 half-year performance, marked by double-digit sales and earnings growth, successful KBU acquisition integration, and an upward revision of adjusted EPS guidance.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.